Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4578460
Max Phase: Preclinical
Molecular Formula: C29H22ClFN4O3
Molecular Weight: 528.97
Molecule Type: Unknown
Associated Items:
ID: ALA4578460
Max Phase: Preclinical
Molecular Formula: C29H22ClFN4O3
Molecular Weight: 528.97
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1cc(C)cc(-n2c(=O)c(C(=O)Nc3ccc(Oc4ccnc(N)c4Cl)c(F)c3)cc3ccccc32)c1
Standard InChI: InChI=1S/C29H22ClFN4O3/c1-16-11-17(2)13-20(12-16)35-23-6-4-3-5-18(23)14-21(29(35)37)28(36)34-19-7-8-24(22(31)15-19)38-25-9-10-33-27(32)26(25)30/h3-15H,1-2H3,(H2,32,33)(H,34,36)
Standard InChI Key: WFEDMZOLLSFUBA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 528.97 | Molecular Weight (Monoisotopic): 528.1364 | AlogP: 6.42 | #Rotatable Bonds: 5 |
Polar Surface Area: 99.24 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.13 | CX Basic pKa: 5.97 | CX LogP: 5.96 | CX LogD: 5.95 |
Aromatic Rings: 5 | Heavy Atoms: 38 | QED Weighted: 0.27 | Np Likeness Score: -1.33 |
1. Cui H, Peng X, Liu J, Ma C, Ji Y, Zhang W, Geng M, Li Y.. (2016) Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold., 26 (18): [PMID:27524312] [10.1016/j.bmcl.2016.07.077] |
Source(1):